Platelet-type 12-lipoxygenase activates NF-κB in prostate cancer cells

https://doi.org/10.1016/S1098-8823(03)00042-XGet rights and content

Abstract

Platelet-type arachidonate 12-lipoxygenase (12-LOX) is highly expressed in many types of cancers and plays an important role in cancer pathophysiology. Arachidonic acid metabolism by 12-LOX results in the stable end product 12(S)-hydroxy eicosatetraenoic acid (12(S)-HETE), which is a signaling molecule with effects on cell proliferation, motility, invasiveness, angiogenesis, and inhibition of apoptosis. The myriad biological activities manifested by 12(S)-HETE appear to be mediated, at least in part, by the activation of NF-κB. Overexpression of the 12-LOX in PC-3 prostate cancer cells resulted in the constitutive activation of the transcription factor. The enzymatic product of arachidonic acid metabolism, 12(S)-HETE, mediates the activation of NF-κB by the 12-LOX. 12(S)-HETE treatment of PC-3 cells induced the degradation of IκB by the S6 proteasomal pathway and the activated NF-κB translocated to the nucleus causing κB-induced transcription. Specificity of the NF-κB activation by 12(S)-HETE was established by the use of a 12-LOX-specific inhibitor and 13(S)-HODE, a known 12(S)-HETE antagonist. Considering the known involvement of MAP kinase pathway in NF-κB activation and that of 12(S)-HETE in MAP kinase pathway, 12-LOX present in prostate cancer tissues may contribute to the constitutive activation of NF-κB in prostate cancer cells.

Introduction

Oxidative metabolism of arachidonic acid by lipoxygenases, especially 12-lipoxygenase (12-LOX), plays an important role in cancer pathophysiology [1], [2], [3]. While 12-LOX exists in three isoforms, viz. platelet-type, leukocyte-type, and epithelial-type [4]; it is the platelet-type enzyme that is widely expressed in tumor cells and its level of expression was correlated with the tumor stage and grade of human prostate carcinoma [5], [6]. 12(S)-Hydroxy eicosatetraenoic acid (12(S)-HETE), the sole and stable end product of arachidonic acid metabolism by the platelet-type 12-LOX, has been shown to protect tumor cells from apoptosis and induce invasion, motility, and angiogenesis [3], [7], [8], [9]. Promotion of such divergent biological functions by 12(S)-HETE is indicative of a complex signaling mechanism leading to metastasis and survival of tumor cells. Attempts at understanding the 12(S)-HETE signaling mechanisms revealed the involvement of PLC/PKC pathway as well as ERK cascade and Src family kinases [10], [11]. The natural convergence point for this vast array of mitogenic signaling mechanisms is the extremely variable transcriptional machinery. One possible integrator of these 12(S)-HETE signaling mechanisms in tumor cells is the pleiotropic transcription factors NF-κB, which play an important role in the control of cell proliferation and apoptosis.

NF-κB is a family of five DNA binding proteins (viz. c-Rel, RelB, p65/RelA, p50/p105, p52/p100) that regulate the expression of a variety of genes involved in host immune responses and inflammation [12]. This family of transcription factors is induced in response to a wide range of signals that lead to cell proliferation, differentiation, regulation of apoptosis, and neoplastic transformation [13], [14], [15]. These transcription factors bind to DNA target sites as homo- or heterodimers and the prototypical NF-κB is a heterodimer of p65 and p50 proteins [16], [17], [18]. In the cytosol these dimeric transcription factors exist in an inactive state where they are bound to any one of several inhibitor proteins collectively known as IκB [19]. The vertebrate IκB family consists of IκBα, IκBβ, IκBε, IκBζ, p105, p100, and Bcl-3 [20], [21]. Activation of NF-κB involves the degradation of IκB by the ubiquitin–proteasome pathway following signal-induced phosphorylation [22], [23]. While normally involved in immune responses and inflammation, a disregulated NF-κB activation can cause undue cell proliferation and inhibition of apoptosis [24], [25]. Indeed, constitutive activation of NF-κB was observed in several different tumors and inhibition of such activation using mutated (degradation resistant) IκBα promoted apoptosis in prostate cancer cells upon TNFα treatment [26]. Given the established role of the platelet-type 12-LOX, hence 12(S)-HETE, to inhibit apoptosis and promote mitogenesis in cancer cells, it is highly probable that NF-κB is involved in the downstream signaling cascade of 12(S)-HETE.

We report here a direct relationship between platelet-type 12-LOX overexpression and NF-κB activation in prostate cancer cells. In addition 12(S)-HETE was shown to induce proteasomal degradation of IκBα, nuclear translocation of NF-κB, and transcriptional activation. Evidence is also presented to directly link the enzymatic activity of platelet-type 12-LOX to NF-κB activation and increased cell viability.

Section snippets

Cell cultures and reagents

PC-3 and Du145 cells were obtained from ATCC and were grown in RPMI-1640 medium, supplemented with 10% fetal bovine serum (FBS) and antibiotics at 37 °C in a 5% CO2 atmosphere. 12-LOX-transfected (nL-8 and nL-12) and mock-transfected (neo) PC-3 cells have previously been developed and characterized in our laboratory [27]. 13(S)-HODE, 12(S)-HETE, 5(S)-HETE, 15(S)-HETE, and arachidonic acid were obtained from Cayman Chemical Company, Ann Arbor, MI. MG-132 was obtained from Biomol Research

Results

Wherever 12-LOX overexpressing cells were used in experiments, both nL-8 and nL-12 clones were used. Since the results obtained were similar for the two clones, only data from either one of the clones was reported.

Discussion

Apart from cyclooxygenase-2, platelet-type 12-LOX is the most commonly expressed arachidonic acid metabolizing enzyme present in a variety of human cancer cells [2], [4], [7] Enhanced expression of platelet-type 12-LOX was observed in many cancers [4] and, in a clinical study, its expression was positively correlated with stage and grade of tumors from prostate cancer patients [5]. 12-LOX-driven metabolism of arachidonic acid produces 12(S)-HETE and this lipid molecule is known for promoting

Acknowledgements

This work was supported by National Institutes of Health Grant CA 29997 and Department of Defense Grant DAMD17-98-1-8502 (both to K.V.H.).

References (73)

  • V.J. Palombella et al.

    The ubiquitin–proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB

    Cell

    (1994)
  • D.J. Van Antwerp et al.

    Inhibition of TNF-induced apoptosis by NF-κB

    Trends Cell Biol.

    (1998)
  • D.H. Lee et al.

    Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae

    J. Biol. Chem.

    (1996)
  • D.H. Lee et al.

    Proteasome inhibitors: valuable new tools for cell biologists

    Trends Cell Biol.

    (1998)
  • D.K. Giri et al.

    Constitutive activation of NF-κB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates

    J. Biol. Chem.

    (1998)
  • F. Chen et al.

    New insights into the role of nuclear factor-κB in cell growth regulation

    Am. J. Pathol.

    (2001)
  • N. Mukaida et al.

    Novel mechanism of glucocorticoid-mediated gene repression. Nuclear factor-κB is target for glucocorticoid-mediated interleukin-8 gene repression

    J. Biol. Chem.

    (1994)
  • R.W. Veltri et al.

    Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer

    Urology

    (1999)
  • H.L. Adler et al.

    Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma

    J. Urol.

    (1999)
  • G. Bonizzi et al.

    Cell type-specific role for reactive oxygen species in nuclear factor-κB activation by interleukin-1

    Biochem. Pharmacol.

    (2000)
  • A. Bowie et al.

    Oxidative stress and nuclear factor-κB activation: a reassessment of the evidence in the light of recent discoveries

    Biochem. Pharmacol.

    (2000)
  • L. Flohe et al.

    Redox regulation of NF-κB activation

    Free Radic. Biol. Med.

    (1997)
  • K. Jung et al.

    Antioxidant enzymes in malignant prostate cell lines and in primary cultured prostatic cells

    Free Radic. Biol. Med.

    (1997)
  • G. Pearson et al.

    ERK5 and ERK2 cooperate to regulate NF-κB and cell transformation

    J. Biol. Chem.

    (2001)
  • K. Tang et al.

    12(S)-HETE in cancer metastasis

    Adv. Exp. Med. Biol.

    (1999)
  • R. Natarajan et al.

    Role of lipoxygenases in breast cancer

    Front. Biosci.

    (1998)
  • X. Gao et al.

    Biological properties of 12(S)-HETE in cancer metastasis

    Adv. Prostaglandin Thromboxane Leukot. Res.

    (1995)
  • J. Timar et al.

    Expression, subcellular localization and putative function of platelet-type 12-lipoxygenase in human prostate cancer cell lines of different metastatic potential

    Int. J. Cancer

    (2000)
  • K.V. Honn et al.

    12-Lipoxygenases and 12(S)-HETE: role in cancer metastasis

    Cancer Metastasis Rev.

    (1994)
  • D. Nie et al.

    Eicosanoid regulation of angiogenesis in human prostate carcinoma and its therapeutic implications

    Ann. N.Y. Acad. Sci.

    (2000)
  • A.S. Baldwin

    Series introduction: the transcription factor NF-κB and human disease

    J. Clin. Invest.

    (2001)
  • D.J. Van Antwerp et al.

    Suppression of TNF-a-induced apoptosis by NF-κB

    Science

    (1996)
  • C.Y. Wang et al.

    NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation

    Science

    (1998)
  • M.L. Schmitz et al.

    The p65 subunit is responsible for the strong transcription activating potential of NF-κB

    EMBO J.

    (1991)
  • L. Cohen et al.

    Heterodimerization and transcriptional activation in vitro by NF-κB proteins

    J. Cell. Physiol.

    (1992)
  • N.D. Perkins et al.

    Distinct combinations of NF-κB subunits determine the specificity of transcriptional activation

    Proc. Natl. Acad. Sci. U.S.A.

    (1992)
  • Cited by (39)

    • High-fat diet activates liver iPLA2γ generating eicosanoids that mediate metabolic stress

      2021, Journal of Lipid Research
      Citation Excerpt :

      Importantly, this study demonstrates that the LOX product 12-HETE is the most predominant oxidized AA metabolite in liver and that it was dramatically elevated (∼2.5-fold) by an HF diet. A number of previous studies have reported multiple detrimental effects of LOX-generated HETE signaling which include induction of oxidative stress during cardiac ischemia/reperfusion and activation of proinflammatory effects via p38MAPK for immune responses by stimulation of cytokine and inflammatory gene expression presumably through activation of G protein-coupled receptor 31 (10, 27–30). Moreover, 12-LOX expression levels and activity were demonstrated to be upregulated in multiple cell types in various disease states (10, 31–33).

    • Spontaneous ultra-weak photon emission in correlation to inflammatory metabolism and oxidative stress in a mouse model of collagen-induced arthritis

      2017, Journal of Photochemistry and Photobiology B: Biology
      Citation Excerpt :

      PGs and TBXs, which are synthesized from arachidonic acid via COX-II pathways, have well-established pro-inflammatory functions [46,47]. The 12/15-LOX products (12-HETE, 15-HETE, and 8-HETE) promote the production of cytokines and activate the NF-κB pathway to inhibit cellular apoptosis [48,49]. In addition, 8-HETE, 12-HETE, and 11-HETE can also be peroxided non-enzymatically by ROS to inhibit apoptosis [50–54]; therefore, these three HETEs may be important inflammatory mediators [55,56].

    • Mammalian lipoxygenases and their biological relevance

      2015, Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
    View all citing articles on Scopus
    View full text